1   Building a resilient antibiotic market—India sets the pace

2   *An econometric modelling approach to estimate revenues in Indian private markets for a novel,*

3   *broad-spectrum intravenous antibiotic*

Leela Maitreyi[1][*][¶], Sreenath Rajagopal[2] [¶], Anand Anandkumar[3], Santanu Datta[4]

Affiliations

1. Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India

2. Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India

3. Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India

4. Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India

[¶]These authors contributed equally to this work

* Corresponding Author:

E-mail: lmaitreyi@bugworksresearch.com

16
17
18
19

Abstract

India faces a mounting health crisis from antibiotic resistance, coupled with global pharmaceutical hesitancy to invest in novel antibiotic research and development (R&D), driven by complex scientific and financial hurdles. India carries one of the world's largest absolute burdens of drug-resistant infections. The combination of a huge infectious-disease caseload, rapid urbanisation, and gaps in sanitation and primary care means that, when resistance emerges, it affects far more patients and generates a much larger pool of patients needing advanced antibiotics than in many high-income countries. Against this backdrop, demand for truly novel, broad-spectrum antibiotics in India is surging, fueled by rising multidrug-resistant infections, overstretched hospitals, and an antibiotic resistance market projected to grow rapidly over the next decade. Most countries respond with incentives and subscription models, for India, the answer lies in bold, innovative revenue strategies and in prioritising the domestic launch of novel antibiotics. This paper presents an econometric analysis of estimated valuation for a novel broad-spectrum antibiotic in India that, as a single therapeutic agent, can address several major hospital-acquired infections, including complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). The model focuses on a hypothetical "ideal" broad-spectrum intravenous antibiotic, and recommends that India pioneer market entry, highlighting financial models that maximise early revenues while still hardwiring stewardship. Launching new antibiotics first in India can catalyse robust real-world use, strengthen domestic pharma, and demonstrate that the economics of antibiotic innovation are viable. This decisive shift can transform India from a passive recipient of ageing drugs into the crucible where the next generation of life-saving antibiotics is forged, anchoring antibiotic research at the core of the country's health security and economic resilience.

Introduction

Launching a novel broad-spectrum antibiotic first in India is a bold and unconventional market entry. It gently challenges the usual Western-first playbook. Since the Industrial Revolution, technology and solutions have often emerged from places under the most pressure. Mass car production and the assembly line, developed in the United States, enabled people to travel across vast distances. The steam engine expanded to move goods across global trade networks. Computers and automation evolved to ease the bottlenecks caused by labour shortages in industry. India now faces some of the world's highest levels of multidrug resistance. It may increasingly contribute to antibiotic innovation.[1-4] Necessity once again encourages invention. It allows a company to step onto the world stage within the antimicrobial resistance (AMR) challenge. Here, the stakes are high, and both impact and sustainable revenues can develop together.

Where the fire burns the hottest

India is widely recognised as one of the major centres of AMR. The country has a large number of deaths associated with multidrug-resistant infections each year. Hospitals face pathogens that increasingly resist last-line drugs [1-5]. In this context, a genuinely novel broad-spectrum antibiotic represents more than an incremental improvement. It can influence mortality trends, intensive care unit (ICU) utilisation, and hospital economics in measurable ways. Introducing such a therapy where the disease burden is highest shapes a narrative of response in which the need is most pressing.

From an overlooked market to a power base

For many years, India and other low- and middle-income countries (LMICs) have often entered the commercial sequence only after Western launches matured. Reversing this sequence could

gradually position India as a strategic base rather than simply a secondary destination. With over

a million multidrug-resistant infections annually and a resistance-focused market already valued

in the billions and growing, India may support a meaningful, premium-positioned antibiotic

franchise rather than merely tail-end market [6, 7]. Being among the early innovators in this

space allows companies to help shape treatment guidelines, stewardship practices, and payer

expectations, rather than compete in a crowded, highly genericised market.

A live laboratory for proof and prestige

An India-first launch means the drug is evaluated under demanding real-world conditions: busy

ICUs, patients presenting late in disease progression, polymicrobial infections, and high levels of

resistance. Demonstrating clinical value in this environment can generate a strong body of real-

world evidence that later supports Western clinical trial dossiers, payer discussions, and pricing

considerations [8-12]. Success in such settings can also bring reputational benefits, positioning

the company not only as an innovator but as one willing to demonstrate its therapy in challenging

healthcare environments.

Economics that bend in your favour

India's development, manufacturing, and commercialisation costs are typically lower than those

in the US or Europe. This can strengthen the economic case for innovation [13-16]. Incremental

clinical success in high-income countries can translate into meaningful system-level benefits in

India. These benefits include shorter hospital stays, fewer salvage regimens, and reduced

catastrophic out-of-pocket spending. Such outcomes support differentiated pricing and maintain

an image of responsible, patient-centred innovation.

Writing a new global script

Choosing India as an early launch market may signal a different type of antibiotic company.

Such a company collaborates closely with global health organisations, AMR initiatives, and

access-oriented partnerships while maintaining a sustainable commercial outlook [17-19]. If

implemented carefully, with stewardship embedded, thoughtful pricing structures, and regional

expansion, India could become a launchpad. This would broaden expectations of where

innovation emerges. Leadership in antibiotic development can flow from Bengaluru and Mumbai

to Boston and Berlin, instead of only the other way around.

In a country like India, where the AMR burden is enormous and hospital systems are already

strained, feeding local epidemiology, utilisation, and cost data into econometric models can

directly translate the AMR burden into projected revenues, budget impact, and ROI for a novel

antibiotic launch [1, 3, 4, 8, 11, 20-22]. These approaches expose the fallacy behind the belief

that "there is no market for new antibiotics." Instead, they show that the problem is not a lack of

demand, but a lack of clear, quantified business cases in the highest-burden countries (Fig.1). A

predictive econometric model is indispensable for estimating revenue in the antibiotics industry.

It elevates forecasting from heuristic extrapolation to a transparent, mechanistic representation of

how infections, resistance, and clinical decision-making create demand [21-26].

For a soon-to-be-launched novel antibiotic, such a model can assimilate country-level incidence

of multi-drug resistant (MDR)/extensively drug-resistant (XDR) pathogens, current

standard-of-care pathways, stewardship constraints, and pricing assumptions to generate

internally coherent projections of volume and revenue over time. This structure also enables

rigorous scenario analysis, varying guideline inclusion, formulary tiering, competitive entries,

and access policies, to delineate a credible range of commercial outcomes rather than a single,

opaque point estimate.

For a preclinical, hypothetical "ideal" broad-spectrum intravenous (IV) antibiotic positioned in

an India-first context, this approach is even more valuable. The model can ingest local

surveillance data, ICU and ward utilisation, length-of-stay distributions, and cost structures. It

converts a qualitative AMR burden into a quantified future addressable market, budget impact,

and risk-adjusted return on investment. The model helps dismantle the narrative that "there is no

market for new antibiotics." It reveals that the real deficit is the absence of robust business cases

anchored by multiple models in high-burden settings [1, 20-24, 27].

Methods

The paper focuses on building predictive revenue models for the launch of the novel broad-

spectrum antibiotic Drug A and a hypothetical "ideal" broad-spectrum IV antibiotic in India.

These models were built around real clinical burden indicators, including AMR prevalence, ICU

admission rates, infection incidence, and hospital-acquired infection frequencies, to estimate

structurally necessary treatment volumes [1, 4, 21, 25, 28, 29]. The key indications represented

mathematically in these models are complicated urinary tract infection (cUTI), hospital-acquired

pneumonia (HAP) and ventilator-acquired pneumonia (VAP). Long-term AMR trend projections

are modelled for both approved antibiotics and the candidate therapy to assess revenue durability

and demand stability under increasing resistance pressures. The combined framework produces

revenue estimates grounded in mandatory clinical use, guideline inclusion, and patient access

and affordability, delivering realistic and financeable forecasts. Because drug revenues are

driven by biological uncertainty, policy behaviour, and market dynamics simultaneously, and no

single model can capture all three, the paper uses multi-model forecasting (Fig.2):

Epidemiological models estimate the number of patients who need the drug based on

disease burden and resistance patterns. This model projects the addressable patient pool for novel

broad-spectrum antibiotics by integrating India-specific epidemiology of cUTI and HAP/VAP

[1, 21, 23, 25, 30-32]. The input data are shown in the supplementary materials.

A market-based model was built to estimate revenue for new broad-spectrum antibiotics

using a market segmentation approach that divides India's total antibiotics market by IV

formulation, novelty (innovator vs generic), and AWaRe category (Fig.3)

(Access/Watch/Reserve). IV antibiotics dominate hospital settings (e.g., 50-60% value in tertiary

care for severe MDR cases), innovators command premiums in Reserve (1% volume but high

value due to scarcity), versus generics flooding Access/Watch (Watch: 34% volume)[16, 33-35].

The input data are shown in the supplementary materials.

Hospital Bed Model estimates antibiotic revenue by anchoring demand to physical

healthcare capacity rather than to total patient counts alone. The model accounts for the total

number of functional hospital beds (public and private), segmented into general and ICU beds.

Bed occupancy rates were applied to estimate active patient-days per year. Standard-of-care

(SOC) guideline eligibility filters were applied to identify cases in which the new antibiotic

would be clinically indicated. Treatment volume was computed by multiplying the number of

eligible cases by the duration of the new antibiotic course**.** Beds are fixed infrastructure assets,

budgets are allocated per bed, and infections scale with bed-days , so revenue forecasts become

capacity-linked**,** budget-anchored, and stewardship-safe, rather than inflated by retail prescription

assumptions. This model turns antibiotic revenue into infrastructure-linked cash flow**.** The input

data are shown in the supplementary materials. [1, 17, 20, 21, 28, 29, 36-38].

Input data and model structure

Within each of the 3 models, 3 scenarios were built in: Base case (Pragmatic, highly

conservative), upside case (Best case, still conservative), downside case (Cynical)

Indian pharmaceutical multi-year financial metrics and performance indicators were curated

from open-source reports for 10 companies. From this data, the key financial metrics were

calculated as %: Cost of goods (COGS), Selling, general & administrative expenses (SG&A),

R&D, Capital expenses (CAPEX). The mean and median financial metrics for these companies

were used as model parameters. All model assumptions, formulae & quantitative input data are

provided in the supplementary.

Two case studies were modelled in this paper:
Drug A-With the following specifications:

Spectrum**:** Novel beta-lactamase/beta-lactamase inhibitor (BL/BLI) class antibiotic

designed and developed to treat life-threatening, multidrug-resistant (MDR) Gram-negative

bacterial infections, which are a major global health challenge. The mechanism allows this drug

to effectively combat "superbugs," including those resistant to carbapenems (the current gold

standard treatments)

Positioning**:** For high-risk cUTI and HAP/VAP in ICU settings

Launch Timeline**:** To launch in India by 2026

Hypothetical "Ideal" broad-spectrum IV antibiotic was considered to fulfil the following

specifications:

Spectrum: Developed to address multidrug-resistant (MDR) Gram-negative bacterial

infections, all CRE, Carbapenem-resistant *Acinetobacter baumannii* (CRAB), Carbapenem-

resistant *Pseudomonas aeruginosa* (CRPA) and is a novel bacterial topoisomerase inhibitor

(NBTI) class

Positioning: For high-risk cUTI and HAP/VAP in ICU settings

Estimated Launch Timeline**:** To launch in India by 2031

The models for these two antibiotics were built using the discounted cash flow

(DCF)methodology. DCF [39-42]models for new antibiotics forecast value by discounting future

cash flows from projected sales at a high-risk Weighted Average Cost of Capital (WACC) 10-

15%), capturing India-specific dynamics such as market penetration, stewardship caps, and MDR

caseload elasticity [1, 17, 21, 39-47].

Core Structure**:** 10-15 year explicit forecasts project revenue ramp using a $100M & $50M sunk

cost for market entry & preclinical assets resp. (sales/marketing heavy upfront), capex (initial

launch infrastructure), and corporate tax. Terminal value assumes 3-5% perpetual growth amid

sustained AMR.

Key Parameters**:** Peak sales (India ICU focus), SoC failure substitution (meropenem/Ceftazidime

/ Avibactam)[1, 17, 47-49], sensitivity to penetration, pricing elasticity.

Using multiple model types allowed us to triangulate revenue from clinical necessity, pricing

sensitivity, adoption speed, and resistance evolution simultaneously, producing forecasts that are

resilient to biological, regulatory, and economic uncertainty — something a single-model

forecast cannot deliver.

Results

All simulated scenarios are presented in the Supplementary Materials.

The results (Fig.4)(Fig.5) show the model's outputs across different simulated scenarios.

27 scenarios are in the mean category & median category each

Best of the median and mean scenarios are illustrated in the heat maps (Fig. 4, Fig.5)

The same modelling framework was used for both case studies.

This allows the outcomes to be compared under a consistent analytical approach.

Model evaluation under the specified scenarios reveals distinct patterns in system behaviour,

summarised as follows:

Case-1: Preclinical hypothetical "ideal" broad-spectrum IV antibiotic

54 scenarios were simulated. Scenarios are combinations of base/pragmatic, best and worst cases

across the 3 models explained in the methods section. Out of the 54 scenarios highlighted, peak

revenue is in the range of $13.8 million to $1406 million. 8 scenarios show net positive NPV &

positive ROI, measured through IRR in the range of 1.57%-15.65%

Case-2: Soon-to-be-launched Drug A

54 scenarios were simulated Out of the 54 scenarios highlighted, peak revenue is in the range of

$14 million to $1434 million, 28 scenarios show net positive NPV & positive ROI, measured

through IRR in the range of 0.02%-76%

Key takeaways from the 2 case studies

For the preclinical asset: IRR is mostly negative because an antibiotic company has all the costs

but none of the monetizable value yet, while facing significant time, failure, and pricing risks.In

financial terms, its projected cash flows are highly negative and heavily discounted, long capital

lock-up before any revenue, extreme probability-of-failure multipliers, stewardship caps revenue

because the drug is intentionally positioned to be underused and cannot be aggressively

marketed. Resistance shrinks product life, so terminal revenue is structurally smaller than

oncology, rare disease, or chronic drugs. Additionally, our models are shown to be extremely

conservative in terms of market penetration rate-very conservative at 8%,10% &12 % of SOC

displacement rates, COGS/CAPEX-highly aggressive estimate, using the financial metrics of the

10 Indian pharma companies that have small molecules and biologics in their pipeline. The

actual COGS for a small-molecule drug is far lower and is expected to be even lower for a non-

BL/BLI class. Very conservative per-course treatment cost at $1000 shown. Very aggressive

development cost shown at $50Million from R&D to market

For a soon-to-be-launched asset**:** IRR is positive because once an antibiotic asset reaches the

clinical stage, the entire financial structure of the project changes, because biological uncertainty

becomes smaller with time. Clinical-stage assets have already cleared the most stringent

scientific filters. As the probability of success rises, expected terminal cash flows jump

dramatically, instantly lifting the IRR. Time to Revenue Shrinks. Time to revenue is

considerably shorter for clinical-stage assets. While early-stage discovery programs may take

12–15 years to reach commercialisation, clinical-stage assets are typically only 3–6 years away

from potential revenue generation. Accordingly, our models apply a 10% discount rate for

market-ready assets and a 15% discount rate for preclinical assets, ensuring conservative and

risk-adjusted DCF estimates. Every clinical milestone doubles or triples the enterprise value.

Manufacturing Economics are Visible. COGS, scale curves, and pricing bands become known,

making margins financeable. This makes revenue models credible and lowers discount rates.

Clinical-stage assets reach cash breakeven much faster, dramatically improving IRR even if

lifetime revenues are modest. As a result, the lens moves from "Long, uncertain, distant upside"

to "Shorter, de-risked, credible cashflows" and IRR becomes positive even in this paper. This

paper aims to address factors that make a compelling case for developing, trialling, and

launching a novel broad-spectrum antibiotic in India first, while achieving reasonable revenues

and protecting stewardship.

Discussion

Preclinical antibiotic assets typically demonstrate scenarios, and negative IRRs because they face long development timelines, high biological failure risk, and distant, heavily discounted future cash flows. Their key bottlenecks include scientific uncertainty, lack of contractable demand, limited manufacturing visibility, and structurally capped revenue potential due to stewardship-driven volume suppression [22, 43-45, 50-53]. In contrast, clinical-stage antibiotic companies demonstrate rapidly improving NPVs and positive IRRs, driven by reduced development risk, shorter time-to-market, eligibility for early procurement contracts, and clearer manufacturing economics [22, 24, 44, 45, 50, 52, 54]. Crucially, India represents a particularly effective launch platform for a novel antibiotic, enabling both meaningful public health impact and commercial sustainability. High levels of antimicrobial resistance create urgent clinical demand, while the country's manufacturing cost advantages allow affordable pricing without compromising margins.[1-5, 35]. Together, these structural features transform uncertain retail demand into predictable institutional cashflows, lowering discount rates and accelerating payback periods—thereby converting previously negative-NPV antibiotic assets into financeable, positive-IRR infrastructure-grade businesses**.**

Our probabilistic forecasting framework integrates AMR prevalence, ICU and hospital bed capacity, stewardship-driven prescribing constraints, cost sensitivity, and market-penetration dynamics to simulate multiple real-world launch scenarios for a novel broad-spectrum IV antibiotic in India. By explicitly modelling uptake against high-resistance standard-of-care (SOC) pathways and protocol-restricted prescribing, the framework estimates mandatory clinical demand rather than aspirational market size. Domestic manufacturing cost curves are layered to define affordable yet commercially sustainable pricing corridors. Resistance trend projections and guideline-integration timelines are incorporated to test the durability of long-term demand

and the stability of revenue. We further apply multi-model sensitivity analysis, stress-testing

worst-case, best-case, and pragmatic scenarios across market archetypes, financial metrics (NPV,

IRR, payback), penetration rates, cost structures, and forecasting methodologies. Across all

modelled cases, the analysis consistently demonstrates predictable institutional volumes, budget-

compatible margins, and accelerated payback periods, providing a robust, data-driven basis for

positioning India as an optimal global launchpad for this product.

Our probabilistic forecasting models highlight the following:

WATCH-category antibiotics generate the highest revenues because they are used broadly as

empiric therapy during epidemic and outbreak conditions, when first-line ACCESS options

fail due to resistance, creating rapid, large-scale, hospital-wide uptake that drives exceptional

but episodic revenue surges. This is the most ambitious scenario and an unlikely model to be

adopted under normal infection conditions in India. This revenue behaviour is unique to

epidemic dynamics, in which the WATCH drugs sit at the exact inflexion point between

ACCESS failure and RESERVE restriction, allowing high-volume deployment before

stewardship ceilings are triggered.

RESERVE-category antibiotics, by contrast, show structurally lower revenues because they

are tightly restricted to salvage therapy, limiting volumes even in high-burden AMR

environments despite their higher per-course prices.

Market penetration assumptions of 6%, 10%, and 12% remain conservative because existing

SOC carbapenems exhibit high and rising resistance across Indian ICU pathogens, forcing

clinicians to escalate empiric therapy rapidly — structurally expanding the eligible treatment

population. In high-resistance hospital settings, empiric escalation often exceeds these

penetration bands, particularly during ventilator-associated pneumonia clusters, underscoring the

modelled penetration levels' intentional caution.

A total development-to-launch cost of approximately USD 50 million is a reasonable estimate

for a non-BL/BLI antibiotic, reflecting shorter clinical pathways, narrower chemistry

complexity, LMIC-based trial efficiencies, and domestic manufacturing scale that materially

compresses development and commercialisation expenditure.

India's scale dwarfs perception: The absolute burden translates into substantial revenue potential

even at modest pricing, if positioning is empiric for ICU.

Quantifies "no market" myth: Models show demand exists, but requires multi-model business

cases

Why launch in india first?

India provides a distinctive setting in which stewardship, access, and commercial sustainability

for novel antibiotics can coexist. The country's high burden of antimicrobial resistance and

hospital-acquired infections creates durable baseline demand for clinically appropriate use, even

under responsible stewardship. At the same time, India's cost-efficient pharmaceutical

manufacturing ecosystem enables innovators to achieve sustainable margins through scale rather

than high per-course pricing. Early inclusion in national treatment guidelines can further secure

durable first-mover advantages through institutional procurement and formulary adoption.

Together, these factors position India not only as a viable early launch market but also as a

platform for generating real-world evidence that may inform adoption in other low- and middle-

income settings and potentially de-risk entry into high-income markets.

This study evaluates the principal economic drivers of such a launch strategy. Specifically, it

estimates the burden of hospital-acquired infections in India that could be addressed by a novel

broad-spectrum intravenous antibiotic and quantifies the addressable patient cohort after

applying stewardship criteria. The analysis models stewardship caps that preserve long-term drug

durability while maintaining commercial viability and assesses pricing architecture and revenue

trajectories over a fifteen-year horizon. Using conservative, base, and optimistic scenarios, we

estimate peak revenues, break-even points, and internal rates of return, while incorporating cost-

of-goods assumptions to guide sustainable per-course pricing.

Several factors lie beyond the scope of the present analysis. The model does not incorporate

policy incentives or financing mechanisms such as grants, tax credits, market-entry rewards, or

subscription models that could further strengthen antibiotic development economics. Intellectual

property and data-exclusivity frameworks, post-approval stewardship commitments, and

potential revenues from out-licensing or royalty agreements are also excluded. In addition, the

analysis does not model expansion of this approach to other low- and middle-income markets or

the potential for Indian market validation to influence launches in Europe or North America.

Finally, the study focuses on intravenous formulations and does not estimate revenue potential

for oral, inhalable, or topical antibiotic products.

330   Conclusions

331   While much of the AMR economics literature portrays antibiotic markets as structurally broken,

332   India offers a setting where stewardship, access, and commercial sustainability can coexist. Its

333   high burden of hospital-acquired infections and drug-resistant Gram-negative pathogens creates a

334   durable baseline demand, even under responsible stewardship, making it a viable early-launch

335   environment for novel intravenous broad-spectrum antibiotics [1-4, 22, 38].

In many Indian tertiary hospitals, antibiotic prescribing is guided by clinical protocols and

supervision, supporting appropriate treatment volumes within stewardship frameworks.

Stewardship, therefore, stabilises institutional demand rather than eliminating revenue. This

effect is reinforced by India's expanding publicly financed healthcare infrastructure:

procurement systems and insurance schemes such as Ayushman Bharat convert fragmented

patient spending into pooled, budget-anchored demand, lowering revenue volatility while

maintaining affordability through negotiated pricing [1, 17, 24, 36, 37, 43, 47, 55-59].

India's manufacturing ecosystem further aligns access with innovation, enabling the production

of novel antibiotics at low marginal cost while remaining commercially viable through scale.

Early inclusion in national treatment guidelines can also create first-mover advantages through

physician standardisation and institutional procurement preference, positioning India as both a

revenue base and a validation platform within a broader launch sequence [15, 38, 60, 61].

Taken together, India suggests that antibiotic markets need not remain structurally broken.

Where stewardship, pooled procurement, manufacturing scale, and guideline integration

converge, access and stewardship can coexist with predictable revenues. Rising incomes and an

estimated 100–300 million upper-middle-class consumers further support uptake of novel

antibiotics priced above generics, challenging perceptions of India as a uniformly low-ability-to-

pay market [62-66].

Acknowledgement

We thank the leadership team at Bugworks Research, including Dr. Balasubramanian V

357   [COO], Shahul Hameed [CSO], Dr. Vasan Sambandamurthy [SVP], and Dr Vasanthi

358   Ramachandran [VP] for their encouragement and institutional support during the development of

359   this work.

References

1.   Antimicrobial Resistance Research and Surveillance Network: Annual Report
2024: Indian Council of Medical Research; 2024 [cited 2025]. Available from:
https://www.icmr.gov.in/icmrobject/uploads/Report/1763981012_icmramrsnannualreport
2024.pdf.
2.   Priyadarshini S. Most drug-resistant infections go untreated in India, study finds
2025 [cited 2025]. Available from: https://www.nature.com/articles/d44151-025-00075-5.
3.   The burden of antimicrobial resistance (AMR) in India: Institute for Health Metrics
and Evaluation; 2023 [cited 2025]. Available from:
https://www.healthdata.org/sites/default/files/2023-09/India.pdf.
4.   Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in
2019: a systematic analysis. Lancet. 2022;399(10325):629–55. Epub 20220119. doi:
10.1016/S0140-6736(21)02724-0. PubMed PMID: 35065702; PubMed Central PMCID:
PMCPMC8841637.
5.   WHO Model List of Essential Medicines - 23rd list: WHO; 2023 [cited 2025].
Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02.
6.   India Antibiotics Market Size & Outlook, 2025-2033: Grand View Research, Inc.;
2024 [cited 2025]. Available from:
https://www.grandviewresearch.com/horizon/outlook/antibiotics-market/india.
7.   Antibiotic resistance market trends and forecast 2024-2032: Polaris Market
Research & Consulting, Inc.; 2024 [cited 2025]. Available from:
https://www.polarismarketresearch.com/industry-analysis/antibiotic-resistance-market.
8.   Chakrabarti A, Balaji V, Bansal N, Gopalakrishnan R, Gupta P, Jain A, et al.
NAMS task force report on antimicrobial resistance. Annals of the National Academy of
Medical Sciences (India). 2025;61(2025):171–209. doi: 10.25259/anams_tfr_13_2024.
9.   Tomar A. 83% Indians carry antibiotic-resistant bacteria, finds study: Times of
India; 2025 [cited 2025]. Available from:
https://timesofindia.indiatimes.com/city/hyderabad/83-indians-carry-antibiotic-resistant-
bacteria-finds-study/articleshow/125419630.cms.
10.   Sharma A, Thakur N, Thakur A, Chauhan A, Babrah H. The Challenge of
Antimicrobial Resistance in the Indian Healthcare System. Cureus. 2023;15(7):e42231.
Epub 20230721. doi: 10.7759/cureus.42231. PubMed PMID: 37605711; PubMed
Central PMCID: PMCPMC10440008.
11.   Real-World Evidence: U.S. Food and Drug Administration; 2025 [cited 2025].
Available from: https://www.fda.gov/science-research/science-and-research-special-
topics/real-world-evidence.
12.   Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What Is Real-World
Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value

Health. 2017;20(7):858–65. Epub 20170511. doi: 10.1016/j.jval.2017.03.008. PubMed
PMID: 28712614.
13.   Independent market research on the global and indian CRO and CDMO market:
Anthem Biosciences; 2025 [cited 2025]. Available from: https://anthembio.com/wp-
content/uploads/2025/08/Independent-Market-Research-on-the-Global-and-Indian-
CRO-and-CDMO-Market-dated-June-17-2025.pdf.
14.   Agrawal S. Indian pharma industry: A comprehensive analysis 2025 [cited 2025].
Available from: https://pharmabiz.com/ArticleDetails.aspx?aid=181382&sid=21.
15.   Sriram Shrinivasan RS, and Anik Ganguly. Healing the World: A Roadmap for
Making India a Global Pharma Exports Hub: Bain & Company; 2025 [cited 2025].
Available from: https://www.bain.com/insights/healing-the-world-a-roadmap-for-making-
india-a-global-pharma-exports-hub.
16.   Indian Pharmaceutical Industry: India Brand Equity Foundation; 2025 [cited
2025]. Available from: https://www.ibef.org/industry/pharmaceutical-india.
17.   India's Antimicrobial Resistance Surveillance & Research Initiative
Collaborations: Indian Council of Medical Research; 2025 [cited 2025]. Available from:
https://iamrsn.icmr.org.in/index.php/collaborations.
18.   Navin Dang ASaVS. Fighting back against antimicrobial resistance: Partnerships
and innovations: Hindustan Times; 2024. Available from:
https://www.hindustantimes.com/ht-insight/public-health/fighting-back-against-
antimicrobial-resistance-partnerships-and-innovations-101732608356795.html.
19.   Maitreyi L, Sambandamurthy VK. Catalyzing Change: Entrepreneurs from the
Global South Leading the Fight against Antimicrobial Resistance. ACS Infect Dis.
2025;11(10):2646–57. Epub 20250929. doi: 10.1021/acsinfecdis.5c00565. PubMed
PMID: 41020570.
20.   Prinja S, Chugh Y, Rajsekar K, Muraleedharan VR. National Methodological
Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in
India. Appl Health Econ Health Policy. 2021;19(6):811–23. Epub 20210629. doi:
10.1007/s40258-021-00668-y. PubMed PMID: 34184237; PubMed Central PMCID:
PMCPMC8238667.
21.   Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et
al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget
Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. Epub
20131213. doi: 10.1016/j.jval.2013.08.2291. PubMed PMID: 24438712.
22.   A financial model for an impact investment fund for the development of
antibacterial treatments and diagnostics.: World Health Organization; 2020 [cited 2025].
Available from: https://www.who.int/docs/default-source/antimicrobial-resistance/a-
financial-model-for-an-impact-investment-fund-for-the-development-of-antibacterial-
treatments-and-diagnostics%281-june%29.pdf.
23.   Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al.
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling
Good Research Practices Task Force--6. Value Health. 2012;15(6):835–42. doi:
10.1016/j.jval.2012.04.014. PubMed PMID: 22999133.
24.   Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a
change in how new antibiotics are reimbursed: Development of an insurance framework
for funding new antibiotics based on a policy of risk mitigation. Health Policy.

2017;121(10):1025–30. Epub 20170805. doi: 10.1016/j.healthpol.2017.07.011. PubMed PMID: 28888660.

25.   Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7:98. Epub 20180809. doi: 10.1186/s13756-018-0384-3. PubMed PMID: 30116525; PubMed Central PMCID: PMCPMC6085682.

26.   Garrison LP, Jr., Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326–35. doi: 10.1111/j.1524-4733.2007.00186.x. PubMed PMID: 17888097.

27.   Collaborators GBDAR. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199–226. Epub 20240916. doi: 10.1016/S0140-6736(24)01867-1. PubMed PMID: 39299261; PubMed Central PMCID: PMCPMC11718157.

28.   Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. N Engl J Med. 2018;379(18):1732–44. doi: 10.1056/NEJMoa1801550. PubMed PMID: 30380384; PubMed Central PMCID: PMCPMC7978499.

29.   Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP. The variability of critical care bed numbers in Europe. Intensive Care Med. 2012;38(10):1647–53. Epub 20120710. doi: 10.1007/s00134-012-2627-8. PubMed PMID: 22777516.

30.   Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: incidence and risk factors. J Infect Dev Ctries. 2009;3(10):771–7. Epub 20091215. doi: 10.3855/jidc.396. PubMed PMID: 20009278.

31.   Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41(2):285–95. Epub 20141216. doi: 10.1007/s00134-014-3603-2. PubMed PMID: 25510301.

32.   Prakash V, Lewis JS, 2nd, Herrera ML, Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2009;53(3):1278–80. Epub 20090105. doi: 10.1128/AAC.01519-08. PubMed PMID: 19124661; PubMed Central PMCID: PMCPMC2650586.

33.   Sood N, de Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff (Millwood). 2009;28(1):w125–37. Epub 20081216. doi: 10.1377/hlthaff.28.1.w125. PubMed PMID: 19088100; PubMed Central PMCID: PMCPMC3829766.

34.   The Global Use of Medicines 2023: IQVIA; 2023 [cited 2025]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2023.

35.   AWaRe classification of antibiotics for evaluation and monitoring of use, 2023: WHO; 2023 [cited 2025]. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04.

36.   National Health Profile 2023: Central bureau of health intelligence, Directorate
General of Health Services, Ministry of Health & Family Welfare, Government of India;
2024 [cited 2025]. Available from:
https://cbhidghs.mohfw.gov.in/sites/default/files/NHP/NHP-2023-Last-Final.pdf.
37.   Annual Report 2023-24: Department of Health & Family Welfare, Ministry of
Health & Family Welfare, Government of India; 2024 [cited 2025]. Available from:
https://www.mohfw.gov.in/sites/default/files/Annual%20Report%202023%2024%20DoH
FW%20English_0.pdf.
38.   Guidelines on Core Components of Infection Prevention and Control
Programmes at the National and Acute Health Care Facility Level: World Health
Organization; 2016 [cited 2025]. Available from:
https://iris.who.int/server/api/core/bitstreams/d811a2ad-3c7f-48a2-b88b-
4935da71a87b/content.
39.   Mazumdar ACaS. Biotech asset valuation methods: A practitioner's guide:
Journal Of Investment Management; 2024 [cited 2025]. Available from:
https://www.analysisgroup.com/globalassets/insights/publishing/2024-biotech-asset-
valuation-methods.pdf.
40.   Valuation handbook —international guide to cost of capital: Kroll, LLC; 2022
[cited 2025]. Available from: https://www.cfainstitute.org/sites/default/files/-
/media/documents/article/industry-research/igcc-summary-edition-2022.pdf.
41.   Damodaran A. Costs of capital by industry sector: NYU Stern School of
Business; 2025 [cited 2025]. Available from:
https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/wacc.htm.
42.   Harrington SE. Cost of Capital for Pharmaceutical, Biotechnology, and Medical
Device Firms. SSRN Electronic Journal. 2009. doi: 10.2139/ssrn.1512938.
43.   Tackling antimicrobial resistance ensuring sustainable R&D: Organisation for
Economic Co-operation and Development; 2017 [cited 2025]. Available from:
https://www.oecd.org/content/dam/oecd/en/topics/policy-sub-issues/antimicrobial-
resistance-and-pandemics/g20-amr-final-paper-2017.pdf.
44.   Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical
assessment of incentive strategies for discovery and development of novel antibiotics. J
Antibiot (Tokyo). 2016;69(2):73–88. Epub 20151014. doi: 10.1038/ja.2015.98. PubMed
PMID: 26464014; PubMed Central PMCID: PMCPMC4775540.
45.   Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, et al. Accelerating
global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev
Drug Discov. 2016;15(9):589–90. Epub 20160729. doi: 10.1038/nrd.2016.155. PubMed
PMID: 27469032.
46.   Ella Jaczynska KOaJM-F. Business Model Options for Antibiotics: Learning from
Other Industries: The Royal Institute of International Affairs and the Big Innovation
Centre; 2015 [cited 2025]. Available from: https://carb-x.org/wp-
content/uploads/2018/02/2015_02_01_Business-Model-Options-for-Antibiotics.pdf.
47.   Walia K, Ohri VC, Madhumathi J, Ramasubramanian V. Policy document on
antimicrobial stewardship practices in India. Indian J Med Res. 2019;149(2):180–4. doi:
10.4103/ijmr.IJMR_147_18. PubMed PMID: 31219081; PubMed Central PMCID:
PMCPMC6563731.

48.   Ankita Sharma SaSD. India: Pharmacy to the world: A healing touch with healthy
profits: Invest India; 2020 [cited 2025]. Available from:
https://www.hcipos.gov.in/content/16145791902_compressed.pdf.
49.   Swaminathan S, Routray A, Mane A. Early and Appropriate Use of Ceftazidime-
Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial
Infections in the Indian Scenario. Cureus. 2022;14(8):e28283. Epub 20220822. doi:
10.7759/cureus.28283. PubMed PMID: 36072213; PubMed Central PMCID:
PMCPMC9440350.
50.   Clancy CJ, Nguyen MH. Buying Time: The AMR Action Fund and the State of
Antibiotic Development in the United States 2020. Open Forum Infect Dis.
2020;7(11):ofaa464. Epub 20200930. doi: 10.1093/ofid/ofaa464. PubMed PMID:
33209952; PubMed Central PMCID: PMCPMC7652093.
51.   Towards a new global business model for antibiotics delinking revenues from
sales: Chatham House Working Group; 2015 [cited 2025]. Available from:
https://www.chathamhouse.org/sites/default/files/field/field_document/20151009NewBus
inessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf.
52.   Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical
development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51.
doi: 10.1038/nbt.2786. PubMed PMID: 24406927.
53.   Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Rottingen JA. Delinking
Investment in Antibiotic Research and Development from Sales Revenues: The
Challenges of Transforming a Promising Idea into Reality. PLoS Med.
2016;13(6):e1002043. Epub 20160614. doi: 10.1371/journal.pmed.1002043. PubMed
PMID: 27299990; PubMed Central PMCID: PMCPMC4907461.
54.   DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical
industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33. Epub 20160212.
doi: 10.1016/j.jhealeco.2016.01.012. PubMed PMID: 26928437.
55.   Singh SK, Sengupta S, Antony R, Bhattacharya S, Mukhopadhyay C,
Ramasubramanian V, et al. Variations in antibiotic use across India: multi-centre study
through Global Point Prevalence survey. J Hosp Infect. 2019;103(3):280–3. Epub
20190603. doi: 10.1016/j.jhin.2019.05.014. PubMed PMID: 31170422.
56.   Laxminarayan R, Matsoso P, Pant S, Brower C, Rottingen JA, Klugman K, et al.
Access to effective antimicrobials: a worldwide challenge. Lancet.
2016;387(10014):168–75. Epub 20151118. doi: 10.1016/S0140-6736(15)00474-2.
PubMed PMID: 26603918.
57.   Prinja S, Dixit J, Nimesh R, Garg B, Khurana R, Paliwal A, et al. Impact of health
benefit package policy interventions on service utilisation under government-funded
health insurance in Punjab, India: analysis of Ayushman Bharat Pradhan Mantri Jan
Arogya Yojana (PM-JAY). Lancet Reg Health Southeast Asia. 2024;28:100462. Epub
20240819. doi: 10.1016/j.lansea.2024.100462. PubMed PMID: 39252993; PubMed
Central PMCID: PMCPMC11381884.
58.   Sharma D, Chauhan AS, Guinness L, Mehndiratta A, Dhiman A, Singh M, et al.
Understanding the extent of economic evidence usage for informing policy decisions in
the context of India's national health insurance scheme: Ayushman Bharat Pradhan
Mantri Jan Aarogya Yojana (PM-JAY). BMJ Glob Health. 2024;9(6). Epub 20240610.

doi: 10.1136/bmjgh-2024-015079. PubMed PMID: 38857943; PubMed Central PMCID:
PMCPMC11168173.
59.   Opportunities and challenges in health financing in india: Centre for Social and
Economic Progress; 2025 [cited 2025]. Available from: https://csep.org/wp-
content/uploads/2025/02/Opportunities-and-Challenges-in-Health-Financing-in-India-
1.pdf.
60.   Deepak Jain SP, and Sambit Patra. The Trillion-Dollar Manufacturing Exports
Opportunity for India: Bain & Company; 2022 [cited 2025]. Available from:
https://www.bain.com/insights/the-trillion-dollar-manufacturing-exports-opportunity-for-
india/.
61.   Domestic medicine manufacturing: Contributing to the growth of the indian
pharmaceutical industry: India Brand Equity Foundation; 2023 [cited 2025]. Available
from: https://www.ibef.org/blogs/domestic-medicine-manufacturing-contributing-to-the-
growth-of-the-indian-pharmaceutical-industry.
62.   Poverty and Shared Prosperity 2022: Correcting Course: The World Bank Group;
2022 [cited 2025]. Available from: https://www.worldbank.org/en/publication/poverty-
and-shared-prosperity.
63.   2023 Global Multidimensional Poverty Index (MPI): United Nations Development
Programme; 2023 [cited 2025]. Available from: https://hdr.undp.org/content/2023-global-
multidimensional-poverty-index-mpi.
64.   Kharas H. The emerging middle class in developing countries: The Brookings
Institution; 2010 [cited 2025]. Available from: https://www.brookings.edu/articles/the-
emerging-middle-class-in-developing-countries/.
65.   Shirish Sankhe AM, Gautam Kumra, Lola Woetzel, Sven Smit, and Kanmani
Chockalingam. India's turning point: An economic agenda to spur growth and jobs:
McKinsey & Company; 2020 [cited 2025]. Available from:
https://www.mckinsey.com/featured-insights/india/indias-turning-point-an-economic-
agenda-to-spur-growth-and-jobs.
66.   Committed to India: What next for Indian healthcare? : PwC; 2022 [cited 2025].
Available from: https://www.pwc.in/industries/healthcare/what-next-for-indian-
healthcare.html.

Fig.1: Antibiotic Uptake Across Markets

ECONOMETRIC MODELS

EPIDEMIOLOGY
- High AMR burden in critical infections
- Carbapenem-resistant infections 5x higher than in western countries
- Limited access to effective therapies

MARKET COMPARISON
- Higher market access
- Forward looking stewardship practices
- Extensive unmet need for emperic escalation

HOSPITAL DEMAND
- Large ICU/critical care bed capacity
- High incidence of cUTI and HAP/VAP
- Elevated Demand in tertiary and private hospitals

Fig.2: Econometric models for revenue estimations in India

Fig.3: AWaRe Antibiotic Classification

Fig. 4: Valuation & IRR estimations for a broad-spectrum preclinical asset across different model scenarios

Fig. 5: Valuation & IRR estimations for market-ready Drug-A across different model scenarios